Table 5, Summary of Manufacturer’s Submission - Brivaracetam (Brivlera)

Drug Product	Brivaracetam (Brivlera)
Treatment	Brivaracetam 25 mg to 100 mg twice daily
Comparator(s)	Lacosamide 100 mg to 200 mg twice daily Perampanel 4 mg to 12 mg once daily Eslicarbazepine 400 mg to 800 mg once daily
Study Question	What is the cost of brivaracetam relative to alternative-branded AED drugs such as lacosamide, perampanel, and eslicarbazepine?
Type of Economic Evaluation	Cost comparison
Target Population	As per the indication: as adjunctive therapy in the management of partial- onset seizures in adult patients with epilepsy who are not satisfactorily controlled with conventional therapy
Perspective	Canadian public payer
Outcome(s) Considered	Drug costs
Key Data Sources
Cost	Manufacturer’s submitted and current market price for brivaracetam ODB Formulary list prices for comparators ODB dispensing fees and markups included
Clinical Efficacy	Unpublished network meta-analysis¹²
Harms	Unpublished network meta-analysis¹²
Time Horizon	1 year
Results for Base Case	At ODB list prices, the annual cost of brivaracetam ($3,513.32 per patient) was $274.63^a less than that of lacosamide ($3,787.95^a per patient), $319.30 less than perampanel ($3,832.62 per patient), and $362.66 less than eslicarbazepine ($3,875.98 per patient) when an 8% markup and dispensing fees of $8.83 were included every 30 days

Drug Product

Brivaracetam (Brivlera)

Treatment

Brivaracetam 25 mg to 100 mg twice daily

Comparator(s)

Lacosamide 100 mg to 200 mg twice daily
Perampanel 4 mg to 12 mg once daily
Eslicarbazepine 400 mg to 800 mg once daily

Study Question

What is the cost of brivaracetam relative to alternative-branded AED drugs such as lacosamide, perampanel, and eslicarbazepine?

Type of Economic Evaluation

Cost comparison

Target Population

As per the indication: as adjunctive therapy in the management of partial- onset seizures in adult patients with epilepsy who are not satisfactorily controlled with conventional therapy

Perspective

Canadian public payer

Outcome(s) Considered

Drug costs

Key Data Sources

Cost

Manufacturer’s submitted and current market price for brivaracetam
ODB Formulary list prices for comparators
ODB dispensing fees and markups included

Clinical Efficacy

Unpublished network meta-analysis¹²

Harms

Unpublished network meta-analysis¹²

Time Horizon

1 year

Results for Base Case

At ODB list prices, the annual cost of brivaracetam ($3,513.32 per patient) was $274.63^a less than that of lacosamide ($3,787.95^a per patient), $319.30 less than perampanel ($3,832.62 per patient), and $362.66 less than eslicarbazepine ($3,875.98 per patient) when an 8% markup and dispensing fees of $8.83 were included every 30 days

From: APPENDIX 2, REVIEWER WORKSHEETS

Brivaracetam (Brivlera) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Feb.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Table 5Summary of Manufacturer’s Submission